Loading...
Initial Phase 2 Trial of a Nicotinic Agonist in Schizophrenia
OBJECTIVE: Nicotinic acetylcholine receptors are possible therapeutic targets for schizophrenia, as shown by neurobiological and molecular evidence for deficiencies in expression of α(7)-nicotinic receptors. Patients’ heavy smoking suggests attempted self-medication through this mechanism. The agent...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2008
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3746983/ https://ncbi.nlm.nih.gov/pubmed/18381905 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1176/appi.ajp.2008.07071135 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|